The eighth edition of BIOVISION, the World Life Sciences Forum, closed with the “BIOVISION Next Gem” Awards Ceremony honoring and recognizing excellence in innovation and entrepreneurship among promising start-ups. Xeltis was selected as winner in the Medtech category out of 280 competitors.
Xeltis was honoured with the esteemed 'Next Gem Award in Medtech' from Biovision. The illustrious Selection Committee, awarding Xeltis the prize, represents nearly € 10 billion under management, is chaired by Roman Fleck, Index Ventures and is coordinated by Jean-Marc Soustre, Humaneye Invest.
From initially 280 company evaluations, down to 150 preselections, 37 companies were finally invited to present at the Biovision Investor Conference in Lyon, France. 'This prize is a clear and independent recognition of the quality of the work Xeltis is conducting and the incredibly game-changing impact our technology can have on current clinical practice. The whole Xeltis team and I are excited and honoured to have received this prestigious Award', said Laurent Grandidier, Xeltis CEO.
Biovision, the World Life Sciences Forum, was held between 24-26 March 2013. BIOVISION brings together top decision-makers from the academic, private, policy-making and civil society sectors to translate innovative ideas into actionable solutions for the benefit of citizens. There were more than 3,000 participants from 60 different countries, and 100 media representatives at the conference.
Xeltis is a privately held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery. The company’s proprietary COR (Cardiac Organ Regeneration) technology combines novel biodegradable biomaterials with sophisticated material processing methods to deliver an implant prosthesis that allows patients to regrow organs in their own bodies, using their own cells. The cpmany was founded in 2006 and is based in Zurich.
Please login or sign up to comment.
Commenting guidelines